Drug Overview

Dactolisib is an experimental “smart” targeted cancer drug that blocks the PI3K/mTOR signaling pathway, a key growth and survival network in many cancers. It is not a traditional chemotherapy that attacks all fast‑growing cells. Instead, it is a molecularly targeted therapy designed to interrupt overactive signals inside cancer cells while sparing many normal tissues.

Because it is still investigational, dactolisib is not approved for routine clinical use and is available mainly through clinical trials at specialized cancer centers. It is taken by mouth as a tablet or capsule, typically once or twice daily, and is being studied in both adult and pediatric cancers. Its “smart” profile aims to hit cancer‑driving signals more precisely, while still requiring careful monitoring for side effects.

Generic Name: Dactolisib (also known under research code names such as BEZ235 or NVP‑BEZ235).
US Brand Names: None; dactolisib is an investigational agent and is not marketed under a commercial brand name.
Drug Class: Dual PI3K/mTOR inhibitor / Targeted therapy.
Route of Administration: Oral tablets or capsules, taken by mouth.
FDA Approval Status: Investigational; not currently approved by the U.S. Food and Drug Administration for standard clinical use. Being evaluated in early‑phase clinical trials for solid tumors and certain hematologic cancers.

What Is It and How Does It Work? (Mechanism of Action)

Dactolisib works as a “smart” targeted therapy by blocking the PI3K/AKT/mTOR signaling pathway, one of the most common growth‑control networks turned on in cancer. Many tumors have genetic changes that keep this pathway switched “on,” helping them grow, survive, and resist treatment. Dactolisib is designed to interfere with this pathway at multiple points simultaneously.

At the molecular level, dactolisib is a dual ATP‑competitive inhibitor that binds to the ATP‑binding pocket of both phosphoinositide 3‑kinase (PI3K) and the mammalian target of rapamycin (mTOR). PI3K has several isoforms (α, β, γ, δ), and mTOR exists in two complexes (mTORC1 and mTORC2). By inhibiting both PI3K and mTOR, dactolisib prevents the phosphorylation of key downstream proteins such as AKT and S6K, which are critical for transmitting survival and growth signals inside the cell.

Blocking this pathway slows tumor growth, reduces protein synthesis, and shifts the balance toward programmed cell death (apoptosis). Preclinical studies also suggest that dactolisib may impair DNA‑repair mechanisms by inhibiting related kinases (such as ATM, ATR, and DNA‑PK), making cancer cells more sensitive to treatments like chemotherapy or radiation. Because dactolisib targets multiple nodes in the same signaling axis, it is considered a dual‑targeted “smart” drug rather than a broad‑cell‑killing chemotherapy.

FDA-Approved Clinical Indications

Dactolisib does not currently have any FDA‑approved indications for routine clinical use. It remains an investigational dual PI3K/mTOR inhibitor being explored in early‑phase trials for several cancers.

Oncological uses (in clinical trials)

Advanced solid tumors, including certain breast, renal, and liver cancers, where dactolisib is being tested as a single agent or in combination with chemotherapy, hormone therapy, or other targeted drugs.
Selected hematologic cancers, such as certain lymphomas and leukemias, in early‑phase studies to determine whether dual PI3K/mTOR blockade can improve disease control.
Tumors with known PI3K/AKT/mTOR pathway alterations, including rare hereditary syndromes with overactive PI3K signaling.

Because dactolisib is still in development, it is only available through approved clinical trials at specialized medical centers and is not considered a standard‑of‑care treatment.

Non‑oncological uses (if any)

There are currently no FDA‑approved non‑cancer (non‑oncological) uses for dactolisib. Its development and regulatory focus are entirely on oncology, particularly as a dual PI3K/mTOR inhibitor.

Dosage and Administration Protocols

Dactolisib is given as an oral tablet or capsule, usually once or twice daily. Because it is investigational, doses can vary significantly between trials, cancer types, and combination regimens. Dose‑finding studies have aimed to identify the maximum tolerated dose while maintaining acceptable side effects.

Feature	Description
Standard dose range (investigational)	Early‑phase trials have explored dactolisib in roughly the range of 100–600 mg per day, sometimes divided into twice‑daily dosing, depending on the trial protocol and patient population.
Frequency of administration	Typically once or twice daily, at consistent times, with careful spacing from food in some protocols to avoid changes in drug absorption.
Route of administration	Oral tablets or capsules, swallowed with water; taken consistently with or without food according to the specific study instructions.
Typical treatment duration	Continued for defined cycles (for example, several weeks to a few months), as long as the cancer appears to respond and the patient tolerates the treatment.
Dose adjustments (renal/hepatic insufficiency)	Because dactolisib is investigational, there is no fully established, widely published dose‑adjustment guideline for kidney or liver problems. Any dose changes are made on a case‑by‑case basis by the oncology and trial team, guided by blood counts, liver‑ and kidney‑function tests, and side‑effect profile.

Patients should always follow the dosing schedule given in the clinical‑trial protocol and should not change the dose or timing without medical advice. If a dose is missed and it is close to the next dose, it is usually skipped rather than doubled.

Clinical Efficacy and Research Results

Dactolisib has been studied in early‑phase and preclinical trials mainly from 2010 through the early 2020s, in patients with advanced solid tumors and certain hematologic cancers. Because the drug is still investigational, large‑scale, long‑term survival data from 2020–2025 are limited, and published information tends to come from small dose‑finding and exploratory studies.

In preclinical models, dactolisib has shown strong antitumor activity, leading to tumor growth inhibition and, in some cases, tumor regression when given alone or combined with chemotherapy, hormone therapy, or radiation. Laboratory studies indicate that dual PI3K/mTOR inhibition can induce cell‑cycle arrest and apoptosis in cancer cells that depend on this pathway for survival.

Human phase‑I and early‑phase trials have focused on identifying the highest tolerated dose and initial antitumor activity.

Safety Profile and Side Effects

Dactolisib, as a targeted small‑molecule drug, still causes side effects that require careful monitoring. It is not an immunotherapy, so its safety profile resembles that of other kinase inhibitors, with some overlap with chemotherapy‑related toxicities.

Black Box Warning

There is currently no FDA‑issued Black Box Warning specifically for dactolisib, as it is an investigational agent. However, clinicians closely monitor for metabolic, gastrointestinal, and immune‑related toxicities typical of PI3K/mTOR inhibitors.

Common side effects (>10%)

Metabolic changes, including high blood sugar or insulin‑related abnormalities.
Diarrhea is usually mild to moderate.
Nausea, vomiting, or loss of appetite.
Fatigue or feeling unusually tired.
Skin rash or dry skin.
Mouth sores (mucositis) or sore throat.
Mild changes in liver‑function tests.

Serious adverse events

Severe or persistent diarrhea, leading to dehydration, electrolyte imbalances, or kidney problems.
Significant metabolic disturbances, including very high blood sugar or major changes in blood lipids.
Liver toxicity, with marked rises in liver‑enzyme levels and sometimes jaundice or abdominal discomfort.
Immune‑related or inflammatory effects, such as pneumonitis‑like lung inflammation, which can cause shortness of breath, cough, or low oxygen levels.
Rare but serious allergic or hypersensitivity reactions, including rash, swelling, or difficulty breathing.
Possible increased risk of infections.

Management strategies

For diarrhea or nausea, patients may receive anti‑diarrheal or anti‑nausea medicines, hydration advice, and dietary changes; dose reductions or treatment breaks may be needed if symptoms are severe.
Metabolic changes such as high blood sugar are monitored with regular blood tests; diet, oral medications, or insulin may be adjusted as needed.
For significant liver‑function abnormalities, treatment may be interrupted or the dose reduced, and the patient monitored more frequently until tests improve.
Any symptoms of lung toxicity—such as shortness of breath, cough, or chest pain—should be evaluated promptly; treatment may be paused or stopped.
Patients should report fever, rash, unusual swelling, severe fatigue, or major gastrointestinal symptoms immediately to their oncology team.

Connection to Stem Cell and Regenerative Medicine

There is currently no strong evidence that dactolisib is being used in combination with stem cell transplantation or classical regenerative medicine protocols. Its main development path is within oncology, where it functions as a dual PI3K/mTOR inhibitor rather than a cell‑based or regenerative intervention.

However, because dactolisib affects key signaling pathways that regulate cell growth, survival, and DNA‑repair responses, future research could explore how PI3K/mTOR inhibition influences immune recovery after stem cell transplantation, tissue‑repair signals, or the behavior of tumor‑associated stem‑like cells. At present, such work remains largely preclinical or conceptual, and dactolisib is best understood as an experimental targeted therapy under investigation, not a regenerative medicine tool.

Patient Management and Practical Recommendations

Because dactolisib is still experimental, patients who receive it are typically enrolled in clinical trials at specialized cancer centers. Careful preparation, close monitoring, and clear communication between patients and the oncology team are essential for safety and to generate meaningful research data.

Pre‑treatment tests to be performed

Blood tests: Complete blood count, liver and kidney function, electrolytes, blood sugar, and blood‑lipid levels.
Imaging: CT, MRI, or PET scans to define tumor size, location, and stage before treatment.
Detailed medical history: Review of prior cancer treatments, diabetes or metabolic disorders, liver disease, and current medications.
Infection screening: Tests for active infections if clinically indicated.
Informed consent: Patients must fully understand that dactolisib is investigational, review the benefits and risks, and sign a clinical‑trial consent form.

Precautions during treatment

Patients should take dactolisib exactly as prescribed, at the same times each day, and report any changes in routine medications.
They should monitor blood sugar if they have diabetes or develop symptoms of high blood sugar, and follow diet and medication advice.
Any new or worsening symptoms—such as severe diarrhea, shortness of breath, chest pain, rash, abdominal pain, yellowing of the skin or eyes, or major fatigue—should be reported immediately.
Patients should attend all scheduled clinic visits, blood tests, and imaging studies.

“Do’s and Don’ts” list

DO take dactolisib at the same time each day with water, and follow the oncologist’s instructions about food.
DO stay in close contact with your study or treating team and report any side effects promptly.
DO drink enough fluids, eat a balanced diet, and manage blood sugar as advised.
DO attend all scheduled clinic visits, blood tests, and imaging studies.
DON’T start new medicines, including vitamins, supplements, or over‑the‑counter drugs, without first checking with your oncologist..

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice or a treatment recommendation. Dactolisib is an investigational dual PI3K/mTOR inhibitor that is not currently approved by the U.S. Food and Drug Administration (FDA) for routine clinical use. It is available only through participation in approved clinical trials at qualified medical centers. Individual responses to dactolisib may vary, and outcomes cannot be guaranteed.